Body WeightNCT02558920
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
An observational study of Body Weight and Obesity, run by John Sievenpiper at 1 site in Canada.
Trial summary
Sugars have been implicated in the epidemics of overweight and obesity. This view is supported by lower quality evidence from ecological observations, animal models, and select human trials. Higher level evidence from controlled trials and prospective cohort studies has been inconclusive. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Body Weight, Obesity, Overweight
- What is being tested?
- Fructose-containing Sugars
- Type of treatment
- Pill or oral medicine
- How many people
- 1 participants
- Where
- 1 siteCanada
- Study dates
- 4 Sep 2018to Sep 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All individuals, both children and adults, regardless of health status.
Who may be able to join
- Randomized and non-randomized controlled intervention studies in humans
- Oral fructose-containing sugars intervention
- Presence of a reduced fructose-containing sugars comparator in one of 4 energy controlled designs (substitution, addition, subtraction, or ad libitum)
- Diet duration >=2 weeks
- Viable outcome data
- Prospective cohort studies
Show all 9Show fewer
- Duration >= 1 year
- Assessment of the exposure of food sources of fructose-containing sugars
- Ascertainment of viable outcome data by level of exposure
Who cannot join
- Observational studies or intervention studies with no control group
- IV or parenteral fructose-containing sugars intervention
- Lack of an adequate comparator (i.e. lack of a difference (<5 g) in fructose-containing sugars between the intervention and control diets)
- Ecological, cross-sectional, or retrospective observational studies
- Intervention studies
Trial locations and contacts
1 site in 1 country.
Canada1 site
The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital
Toronto, Ontario, M5C 2T2
About this study
Official title: Important Food Sources of Fructose-Containing Sugars and Markers of Adiposity and Risk of Obesity: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials and Prospective Cohort Studies
Sugars have been implicated in the epidemics of overweight and obesity. This view is supported by lower quality evidence from ecological observations, animal models, and select human trials. Higher level evidence from controlled trials and prospective cohort studies has been inconclusive. Whether sugars contribute to weight gain or increases in adiposity independent of their calories and whether important food sources of sugars other than SSBs are associated with a higher risk of overweight and obesity or weight gain remain unclear. To address the uncertainties, the investigators propose to conduct a series of systematic reviews and meta-analyses of the totality of the evidence from controlled trials and prospective cohort studies to distinguish the contribution of fructose-containing sugars and important food sources of sugars (SSBs, fruit, 100% fruit juice, cakes/sweets, yogurt, cereals, etc) from that of energy in the development of overweight and obesity. The findings generated by this proposed knowledge synthesis will help improve the health of consumers through informing evidence-based guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design
Read the detailed description
Background: Sugars have emerged as one of the most important public health concerns. Attention has focused squarely on fructose-containing sugars (fructose, sucrose, high fructose corn syrup [HFCS], etc.). Collectively, these sugars have been indicted as drivers of the obesity epidemic and its and its downstream cardiometabolic complications. This special view rests on the unique metabolic and endocrine responses to fructose. Unlike glucose, fructose is thought to bypasses negative feedback control acting as an unregulated substrate for de novo lipogenesis and impair satiety signaling resulting in weight gain. In support of these mechanisms, animal models, low-quality ecological studies, and select human trials of overfeeding at levels of exposure far beyond population intakes have reported adverse metabolic effects of sugars. Higher level evidence from systematic reviews and meta-analyses of controlled trials, however, suggests that any effects of sugars are mediated by excess calories rather than the sugars per se. There is also evidence that not all food sources of these sugars are associated equally with obesity. While sugars-sweetened beverages (SSBs) have shown an adverse association with body weight, markers of adiposity and obesity, other important food sources of sugars such as fruit, 100% fruit juice, cereals, yogurts, and even cakes/sweets have shown either no association or a beneficial association. It remains unclear whether sugars contribute to weight gain or increases in adiposity independent of their calories and whether important food sources other than SSBs are associated with a higher risk of overweight and obesity.
Need for proposed research: High quality systematic reviews and meta-analyses of controlled trials and prospective cohort studies represent the highest level of evidence to support dietary guidelines and public health policy development. As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, there is an urgent need for systematic reviews and meta-analyses comparing the role of different food sources of sugars in the development of overweight and obesity.
Objective: The investigators will conduct a series of American Society of Nutrition (ASN)-commissioned systematic reviews and meta-analyses to assess (1) the effect of different important food sources of sugars (e.g. SSBs, fruit, 100% fruit juice, yoghurt, cereals, cakes, pastries, sweets, etc.) at different levels of energy control on body weight and markers of adiposity in controlled trials and (2) their association with incident overweight/obesity and markers of adiposity in prospective cohort studies.
Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms supplemented by hand searches of references of included studies.
Study selection: The investigators will include prospective cohort studies and controlled dietary trials. Prospective cohort studies will be included if they are >= 1-year duration and assess the relation of different sugars (total sugars, sucrose, fructose) or important food sources of added/free sugars (SSBs, pure fruit juice, cakes/sweets, cereals, yoghurt, etc.) with incident overweight/obesity or changes in markers of adiposity. Controlled (randomized and non-randomized) trials will be included if they are >= 2-weeks duration and assess the effect of fructose-containing sugars (fructose, sucrose, high fructose corn syrup, etc) from different food sources (e.g. SSBs, fruit, 100% fruit juice, yoghurt, cereals, cakes, pastries, sweets, etc.) on body weight or markers of adiposity. To allow for the separation of the effect of sugars from that of energy, 4 trial designs will be considered: (1) 'substitution' trials, in which fructose-containing sugars added to foods and beverages are compared with other macronutrient sources (usually starch or other sugars) under energy matched conditions; (2) 'addition' trials, in which fructose-containing sugars supplement a diet with excess energy compared to the same diet alone without the excess energy; (3) 'subtraction' trials, in which energy from fructose-containing sugars (usually in the form of sugars-sweetened beverages) is reduced by displacing it with water and/or no-calorie or low-calorie sweeteners or by eliminating it altogether from the background diet; and (4) 'ad libitum' trials, in which energy from fructose-containing sugars are freely replaced with other sources of energy without any strict control of either the study foods or the background diet.
Data extraction: Two or more investigators will independently extract relevant data and assess risk of bias using the Cochrane Risk of Bias Tool. All disagreements will be resolved by consensus. Standard computations and imputations will be used to derive missing variance data.
Outcomes: The primary outcome will be incidence of overweight/obesity in prospective cohort studies and body weight in controlled trials. Secondary outcomes will include measures of global adiposity (body weight [prospective cohort studies only], body mass index (BMI), and body fat) and measures of abdominal adiposity (waist circumference, waist-to-hip ratio, and visceral adipose tissue).
Data synthesis: Separate analyses will be conducted by level of energy control (substitution, addition, subtraction, ad libitum) and age (children, adults). Risk ratios will be pooled for incident overweight/obesity and mean differences for measures of global and abdominal adiposity using the generic inverse variance method. Random-effects models will be used even in the absence of statistically significant between-study heterogeneity, as they yield more conservative summary effect estimates in the presence of residual heterogeneity. Fixed-effects models will only be used where there is <5 included studies. Paired analyses will be applied for crossover trials. Heterogeneity will be assessed by the Cochran Q statistic and quantified by the I2 statistic. To explore sources of heterogeneity, the investigators will conduct sensitivity analyses, in which each study is systematically removed. If >=10 studies are available, then the investigators will also explore sources of heterogeneity by a priori subgroup analyses by sugar regulatory designation (added, naturally occurring), sugar food form (solid, liquid, or mixed), dose (=<10% energy, >10%), follow-up (=<10-years, >10-years), adjustment for adiposity, adjustment for energy, exposure assessment, dose, outcome ascertainment, risk of bias in prospective cohort studies and health status (metabolic syndrome/diabetes, overweight, normal weight), sugar type (sucrose, fructose, HFCS), sugar regulatory designation (added, naturally occurring), sugar food form (solid, liquid, or mixed), dose (=<10% energy, >10%), comparator (starch, fat, protein in substitution or ad libitum studies), baseline values, randomization, study design (parallel, crossover), energy balance (positive, neutral, negative), follow-up (=<8-weeks, >8-weeks), and risk of bias in controlled trials. Meta-regression analyses will assess the significance of categorical and continuous subgroups analyses. If >=10 studies are available, then publication bias will be investigated by inspection of funnel plots and formal testing using the Egger and Begg tests. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.
Evidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.
Significance: The proposed project will aid in knowledge translation related to the role of dietary fructose-containing sugars and important food sources of these sugars in the development of overweight and obesity, strengthening the evidence-base for guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.
- Conditions
- Body Weight, Obesity, Overweight, Adiposity, Obesity, Abdominal
- Being tested
- Fructose-containing Sugars
- Keywords
- Systematic review and meta-analysis, Evidence-based medicine (EBM), Evidence-based nutrition (EBN), Clinical practice guidelines, Clinical trials, Dietary sugars, Fructose, Sucrose, High fructose corn syrup, Isocaloric, Hypercaloric, Body weight, Prospective cohort studies
- Medical subject headings
- Body Weight, Obesity, Overweight, Obesity, Abdominal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fructose-containing SugarsOther
Also called fructose, sucrose, high-fructose corn syrup (HFCS)
An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
What is being measured
The primary outcome is the main question the study is designed to answer.
Incident overweight or obesity (prospective cohort studies)
Incident overweight or obesity
Measured: Up to 20 years
Body weight (controlled trials)
Body weight
Measured: Up to 20 years
Secondary outcomes (6)
Global measures of adiposity with established clinical relevance - body weight (prospective cohort studies)
Body weight
Measured: Up to 20 years
Global measures of adiposity with established clinical relevance - BMI (prospective cohort studies and controlled trials)
Body mass index (BMI)
Measured: Up to 20 years
Global measures of adiposity with established clinical relevance - body fat (prospective cohort studies and controlled trials)
Body fat
Measured: Up to 20 years
Abdominal measures of adiposity with established clinical relevance - waist circumference (prospective cohort studies and controlled trials)
Waist circumference
Measured: Up to 20 years
Abdominal measures of adiposity with established clinical relevance - waist-to-hip ratio (prospective cohort studies and controlled trials)
Waist-to-hip ratio
Measured: Up to 20 years
Abdominal measures of adiposity with established clinical relevance - Visceral Adipose tissue (prospective cohort studies and controlled trials)
Visceral Adipose tissue (VAT)
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2015 (estimated)
- Study start4 Sep 2018
- Primary completionJan 2020 (estimated)
- Study completionSep 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Body WeightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- John Sievenpiper
- Sponsor type
- University, hospital or other
- Collaborators
- American Society for Nutrition, The Physicians' Services Incorporated Foundation, Canadian Diabetes Association
- Responsible party
- Sponsor-investigator, John Sievenpiper, University of Toronto
- Investigators
- John Sievenpiper, MD,PhD,FRCPC, Principal investigator, University of Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02558920
- Sponsor's protocol ID
- ASN-Sugars 2015
- Status last verified
- Dec 2018
- First submitted
- 15 Sep 2015
- Last updated
- 15 Jan 2019
- Results posted
- No
- Data monitoring committee
- No
Publications
Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, Chiavaroli L, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med. 2012 Feb 21;156(4):291-304. doi: 10.7326/0003-4819-156-4-201202210-00007.
PubMed 22351714Sievenpiper JL, de Souza RJ, Cozma AI, Chiavaroli L, Ha V, Mirrahimi A. Fructose vs. glucose and metabolism: do the metabolic differences matter? Curr Opin Lipidol. 2014 Feb;25(1):8-19. doi: 10.1097/MOL.0000000000000042.
PubMed 24370846Sievenpiper JL, Chiavaroli L, de Souza RJ, Mirrahimi A, Cozma AI, Ha V, Wang DD, Yu ME, Carleton AJ, Beyene J, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. 'Catalytic' doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. Br J Nutr. 2012 Aug;108(3):418-23. doi: 10.1017/S000711451200013X. Epub 2012 Feb 21.
PubMed 22354959Chiavaroli L, Cheung A, Ayoub-Charette S, Ahmed A, Lee D, Au-Yeung F, Qi X, Back S, McGlynn N, Ha V, Lai E, Khan TA, Blanco Mejia S, Zurbau A, Choo VL, de Souza RJ, Wolever TM, Leiter LA, Kendall CW, Jenkins DJ, Sievenpiper JL. Important food sources of fructose-containing sugars and adiposity: A systematic review and meta-analysis of controlled feeding trials. Am J Clin Nutr. 2023 Apr;117(4):741-765. doi: 10.1016/j.ajcnut.2023.01.023. Epub 2023 Feb 23.
PubMed 36842451
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Important Food Sources of Fructose-Containing Sugars and Markers of Adiposity and Risk of Obesity: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials and Prospective Cohort Studies
- ClinicalTrials.gov ID
- NCT02558920
- Acronym / sponsor ID
- ASN-Sugars 2015
- Conditions
- Body Weight, Obesity, Overweight, Adiposity, Obesity, Abdominal
- Keywords
- Systematic review and meta-analysis, Evidence-based medicine (EBM), Evidence-based nutrition (EBN), Clinical practice guidelines, Clinical trials, Dietary sugars, Fructose, Sucrose
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1 participants (estimated)
- Lead sponsor
- John SievenpiperUniversity, hospital or other
- Collaborators
- American Society for Nutrition, The Physicians' Services Incorporated Foundation, Canadian Diabetes Association
- Study start
- 4 Sep 2018 (actual)
- Primary completion
- Jan 2020 (estimated)
- Study completion
- Sep 2020 (estimated)
- First posted
- 24 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sugars have been implicated in the epidemics of overweight and obesity. This view is supported by lower quality evidence from ecological observations, animal models, and select human trials. Higher level evidence from controlled trials and prospective cohort studies has been inconclusive. Whether sugars contribute to weight gain or increases in adiposity independent of their calories and whether important food sources of sugars other than SSBs are associated with a higher risk of overweight and obesity or weight gain remain unclear. To address the uncertainties, the investigators propose to conduct a series of systematic reviews and meta-analyses of the totality of the evidence from controlled trials and prospective cohort studies to distinguish the contribution of fructose-containing sugars and important food sources of sugars (SSBs, fruit, 100% fruit juice, cakes/sweets, yogurt, cereals, etc) from that of energy in the development of overweight and obesity. The findings generated by this proposed knowledge synthesis will help improve the health of consumers through informing evidence-based guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design
Detailed description
Background: Sugars have emerged as one of the most important public health concerns. Attention has focused squarely on fructose-containing sugars (fructose, sucrose, high fructose corn syrup [HFCS], etc.). Collectively, these sugars have been indicted as drivers of the obesity epidemic and its and its downstream cardiometabolic complications. This special view rests on the unique metabolic and endocrine responses to fructose. Unlike glucose, fructose is thought to bypasses negative feedback control acting as an unregulated substrate for de novo lipogenesis and impair satiety signaling resulting in weight gain. In support of these mechanisms, animal models, low-quality ecological studies, and select human trials of overfeeding at levels of exposure far beyond population intakes have reported adverse metabolic effects of sugars. Higher level evidence from systematic reviews and meta-analyses of controlled trials, however, suggests that any effects of sugars are mediated by excess calories rather than the sugars per se. There is also evidence that not all food sources of these sugars are associated equally with obesity. While sugars-sweetened beverages (SSBs) have shown an adverse association with body weight, markers of adiposity and obesity, other important food sources of sugars such as fruit, 100% fruit juice, cereals, yogurts, and even cakes/sweets have shown either no association or a beneficial association. It remains unclear whether sugars contribute to weight gain or increases in adiposity independent of their calories and whether important food sources other than SSBs are associated with a higher risk of overweight and obesity.
Need for proposed research: High quality systematic reviews and meta-analyses of controlled trials and prospective cohort studies represent the highest level of evidence to support dietary guidelines and public health policy development. As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, there is an urgent need for systematic reviews and meta-analyses comparing the role of different food sources of sugars in the development of overweight and obesity.
Objective: The investigators will conduct a series of American Society of Nutrition (ASN)-commissioned systematic reviews and meta-analyses to assess (1) the effect of different important food sources of sugars (e.g. SSBs, fruit, 100% fruit juice, yoghurt, cereals, cakes, pastries, sweets, etc.) at different levels of energy control on body weight and markers of adiposity in controlled trials and (2) their association with incident overweight/obesity and markers of adiposity in prospective cohort studies.
Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms supplemented by hand searches of references of included studies.
Study selection: The investigators will include prospective cohort studies and controlled dietary trials. Prospective cohort studies will be included if they are >= 1-year duration and assess the relation of different sugars (total sugars, sucrose, fructose) or important food sources of added/free sugars (SSBs, pure fruit juice, cakes/sweets, cereals, yoghurt, etc.) with incident overweight/obesity or changes in markers of adiposity. Controlled (randomized and non-randomized) trials will be included if they are >= 2-weeks duration and assess the effect of fructose-containing sugars (fructose, sucrose, high fructose corn syrup, etc) from different food sources (e.g. SSBs, fruit, 100% fruit juice, yoghurt, cereals, cakes, pastries, sweets, etc.) on body weight or markers of adiposity. To allow for the separation of the effect of sugars from that of energy, 4 trial designs will be considered: (1) 'substitution' trials, in which fructose-containing sugars added to foods and beverages are compared with other macronutrient sources (usually starch or other sugars) under energy matched conditions; (2) 'addition' trials, in which fructose-containing sugars supplement a diet with excess energy compared to the same diet alone without the excess energy; (3) 'subtraction' trials, in which energy from fructose-containing sugars (usually in the form of sugars-sweetened beverages) is reduced by displacing it with water and/or no-calorie or low-calorie sweeteners or by eliminating it altogether from the background diet; and (4) 'ad libitum' trials, in which energy from fructose-containing sugars are freely replaced with other sources of energy without any strict control of either the study foods or the background diet.
Data extraction: Two or more investigators will independently extract relevant data and assess risk of bias using the Cochrane Risk of Bias Tool. All disagreements will be resolved by consensus. Standard computations and imputations will be used to derive missing variance data.
Outcomes: The primary outcome will be incidence of overweight/obesity in prospective cohort studies and body weight in controlled trials. Secondary outcomes will include measures of global adiposity (body weight [prospective cohort studies only], body mass index (BMI), and body fat) and measures of abdominal adiposity (waist circumference, waist-to-hip ratio, and visceral adipose tissue).
Data synthesis: Separate analyses will be conducted by level of energy control (substitution, addition, subtraction, ad libitum) and age (children, adults). Risk ratios will be pooled for incident overweight/obesity and mean differences for measures of global and abdominal adiposity using the generic inverse variance method. Random-effects models will be used even in the absence of statistically significant between-study heterogeneity, as they yield more conservative summary effect estimates in the presence of residual heterogeneity. Fixed-effects models will only be used where there is <5 included studies. Paired analyses will be applied for crossover trials. Heterogeneity will be assessed by the Cochran Q statistic and quantified by the I2 statistic. To explore sources of heterogeneity, the investigators will conduct sensitivity analyses, in which each study is systematically removed. If >=10 studies are available, then the investigators will also explore sources of heterogeneity by a priori subgroup analyses by sugar regulatory designation (added, naturally occurring), sugar food form (solid, liquid, or mixed), dose (=<10% energy, >10%), follow-up (=<10-years, >10-years), adjustment for adiposity, adjustment for energy, exposure assessment, dose, outcome ascertainment, risk of bias in prospective cohort studies and health status (metabolic syndrome/diabetes, overweight, normal weight), sugar type (sucrose, fructose, HFCS), sugar regulatory designation (added, naturally occurring), sugar food form (solid, liquid, or mixed), dose (=<10% energy, >10%), comparator (starch, fat, protein in substitution or ad libitum studies), baseline values, randomization, study design (parallel, crossover), energy balance (positive, neutral, negative), follow-up (=<8-weeks, >8-weeks), and risk of bias in controlled trials. Meta-regression analyses will assess the significance of categorical and continuous subgroups analyses. If >=10 studies are available, then publication bias will be investigated by inspection of funnel plots and formal testing using the Egger and Begg tests. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.
Evidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.
Significance: The proposed project will aid in knowledge translation related to the role of dietary fructose-containing sugars and important food sources of these sugars in the development of overweight and obesity, strengthening the evidence-base for guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All individuals, both children and adults, regardless of health status.
Key inclusion criteria (9 listed)
- Randomized and non-randomized controlled intervention studies in humans
- Oral fructose-containing sugars intervention
- Presence of a reduced fructose-containing sugars comparator in one of 4 energy controlled designs (substitution, addition, subtraction, or ad libitum)
- Diet duration >=2 weeks
- Viable outcome data
Key exclusion criteria (5 listed)
- Observational studies or intervention studies with no control group
- IV or parenteral fructose-containing sugars intervention
- Lack of an adequate comparator (i.e. lack of a difference (<5 g) in fructose-containing sugars between the intervention and control diets)
- Ecological, cross-sectional, or retrospective observational studies
- Intervention studies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fructose-containing SugarsAlso: fructose, sucrose, high-fructose corn syrup (HFCS)An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet | Other | – |
Primary outcome
Incident overweight or obesity (prospective cohort studies)
Time frame: Up to 20 years
Incident overweight or obesity
Body weight (controlled trials)
Time frame: Up to 20 years
Body weight
6 secondary outcomes
Global measures of adiposity with established clinical relevance - body weight (prospective cohort studies)
Time frame: Up to 20 years
Global measures of adiposity with established clinical relevance - BMI (prospective cohort studies and controlled trials)
Time frame: Up to 20 years
Global measures of adiposity with established clinical relevance - body fat (prospective cohort studies and controlled trials)
Time frame: Up to 20 years
Abdominal measures of adiposity with established clinical relevance - waist circumference (prospective cohort studies and controlled trials)
Time frame: Up to 20 years
Abdominal measures of adiposity with established clinical relevance - waist-to-hip ratio (prospective cohort studies and controlled trials)
Time frame: Up to 20 years
Abdominal measures of adiposity with established clinical relevance - Visceral Adipose tissue (prospective cohort studies and controlled trials)
Time frame: Up to 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2019.
- Background: PubMed 22351714Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, Chiavaroli L, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med. 2012 Feb 21;156(4):291-304. doi: 10.7326/0003-4819-156-4-201202210-00007.
- Background: PubMed 24370846Sievenpiper JL, de Souza RJ, Cozma AI, Chiavaroli L, Ha V, Mirrahimi A. Fructose vs. glucose and metabolism: do the metabolic differences matter? Curr Opin Lipidol. 2014 Feb;25(1):8-19. doi: 10.1097/MOL.0000000000000042.
- Background: PubMed 22354959Sievenpiper JL, Chiavaroli L, de Souza RJ, Mirrahimi A, Cozma AI, Ha V, Wang DD, Yu ME, Carleton AJ, Beyene J, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. 'Catalytic' doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. Br J Nutr. 2012 Aug;108(3):418-23. doi: 10.1017/S000711451200013X. Epub 2012 Feb 21.
- Derived from this study: PubMed 36842451Chiavaroli L, Cheung A, Ayoub-Charette S, Ahmed A, Lee D, Au-Yeung F, Qi X, Back S, McGlynn N, Ha V, Lai E, Khan TA, Blanco Mejia S, Zurbau A, Choo VL, de Souza RJ, Wolever TM, Leiter LA, Kendall CW, Jenkins DJ, Sievenpiper JL. Important food sources of fructose-containing sugars and adiposity: A systematic review and meta-analysis of controlled feeding trials. Am J Clin Nutr. 2023 Apr;117(4):741-765. doi: 10.1016/j.ajcnut.2023.01.023. Epub 2023 Feb 23.
Related trials for Body Weight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Sievenpiper, MD,PhD,FRCPC principal investigator
University of Toronto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Body Weight and Obesity, run by John Sievenpiper at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incident overweight or obesity (prospective cohort studies) (time frame: Up to 20 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02558920, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2019.